Keywords
KDM6B
Psychosis
Brief psychotic episode
Categories
Abstract
The 17p13.1 microdeletion is a rare chromosomal abnormality associated with intellectual disability, neurodevelopmental delay, and variable oncologic risk. Alterations involving the KDM6B gene in this region have been linked to neurodevelopmental disorders and, in some cases, psychiatric manifestations. We report the case of a 16-year-old adolescent with a heterozygous 17p13.1 deletion and a prior diagnosis of attention deficit hyperactivity disorder (ADHD) who developed a brief psychotic episode characterized by recurrent visual hallucinations and severe anxiety. The patient showed a favorable response to treatment with an atypical antipsychotic, a selective serotonin reuptake inhibitor, and short-term benzodiazepine use, achieving full remission after three months. This case underscores the potential contribution of rare structural variants to the emergence of psychotic symptoms in adolescents and highlights the importance of a multidisciplinary clinical approach.
References
Van Kampen F, Clark A, Soul J, Kanhere A, Glenn M, Pettitt A, et al. Deletion of 17p in cancers: guilt by (p53) association. Oncogene. 2025;44:637–651. https://doi.org/10.1038/s41388-025-03300-8.
Jin Q, Cheng M, Xia X, Han Y, Zhang J, Cao P, et al. Downregulation of MYH10 driven by chromosome 17p promotes hepatocellular carcinoma metastasis through activation of the EGFR pathway. J Cell Mol Med. 2021;25(24):11142–11156. https://doi.org/10.1111/jcmm.17036.
Yamamoto N, Okazaki S, Kuki I, Yamada N, Nagase S, Nukui M, et al. Possible critical region associated with late-onset spasms in 17p13.1–p13.2 microdeletion syndrome: report of two new cases and review of the literature. Epileptic Disord. 2024;26(3):567–571. https://doi.org/10.1684/epd.2022.1416.
Stoica A, Cristian M, Aschie M, Mitroi A, Cozaru G, Baltatescu G, et al. 17p13.1 deletion in small B-cell lymphocytic lymphomas: prognostic factor and diagnostic approach. Rev Rom Hematol. 2025;3(1):11–17. https://doi.org/10.59854/dhrrh.2025.3.1.11.
Vadillo A. Análisis de la enfermedad residual en el producto de aféresis en pacientes sometidos a autotrasplante hematopoyético [tesis de grado]. Salamanca: Universidad de Salamanca; 2024.
Mogollón P. Evaluación preclínica de mecanismos de resistencia a fármacos inmunomoduladores en mieloma múltiple [tesis de grado]. Salamanca: Universidad de Salamanca; 2021. Disponible en: http://hdl.handle.net/10366/148918.
Tam HL, Chung SF, Lou CK. A review of microdeletion. Hong Kong Med J. 2018;18:58.
Meza Cruz D. Factores de riesgo asociados a microdeleción [tesis de especialidad]. Tijuana: Universidad Autónoma de Baja California, Facultad de Medicina y Psicología, División de Estudios de Posgrado e Investigación; 2021.
Gómez Angelats E, Miró O, Bragulat Baur E, et al. Microdeletions. Emergencias. 2018;30:163–168.
American Psychiatric Association. Manual diagnóstico y estadístico de los trastornos mentales DSM-5. 5a ed. Arlington, VA: American Psychiatric Association; 2014.
Vásquez Alva R, Luna Muñoz C, Ramos Garay CM. Microdeleciones y su afectación en el desarrollo neurológico. Rev Fac Med Hum. 2019;19(1):90–100.
Zachariasse JM, van der Hagen V, Seiger N, et al. Microdeletions: a systematic review and meta-analysis. BMJ Open. 2019;9:e028743.
Carvalho CMB, Vasanth S, Shinawi M, Russell C, Ramocki MB, et al. Dosage changes of a segment at 17p13.1 lead to intellectual disability and microcephaly. Am J Hum Genet. 2014;95(5):565–578.
Rots D, Jakub TE, Keung C, Jackson A, Banka S, Pfundt R, et al. The clinical and molecular spectrum of the KDM6B-related neurodevelopmental disorder. Am J Hum Genet. 2023;110(6):963–978.
Lowther C, Costain G, Stavropoulos DJ, Melvin R, Silversides CK, Andrade DM, et al. 15q13.3 microdeletion phenotype. Genet Med. 2015;17(2):149–157.
Yamamoto N, Okazaki S, Kuki I, Yamada N, Nagase S, Nukui M, et al. Possible critical region associated with late-onset spasms in 17p13.1–p13.2 microdeletion syndrome. Epileptic Disord. 2022;24(3):567–571.
Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Smoller JW, et al. Psychosis with methylphenidate or amphetamine in attention-deficit/hyperactivity disorder. N Engl J Med. 2019;380(15):1128–1138.
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in children and young people: recognition and management (CG155). London: NICE; 2013.
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: treatment and management (CG178). London: NICE; 2014.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Enrique Eduardo Hernandez Aranda, Alejandro Gaviño Vergara, Erika Nayeli Mijangos Moreno, Lourdes Alejandra Magaña Puc, Zoila Patricia López Cárdenas